Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2024-03-25 Regulatory Filings
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Avecho commences Phase III insomnia trial 3 pages 200.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 26 March 2024 about Avecho Biotechnology Limited commencing recruitment for a Phase III clinical trial for insomnia treatment. It provides detailed information about the trial design, regulatory context, market opportunity, and includes forward-looking statements. There are no financial statements, quarterly or annual results, or audit information. The document is a corporate announcement about a clinical trial commencement, not a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information rather than just announcing a report release. The content fits best under a general regulatory announcement category for corporate news that does not fit other specific categories. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-03-25 English
Avecho to present at NWR Virtual Healthcare Conference 1
Regulatory Filings Classification · 90% confidence The document is an ASX announcement dated 18 March 2024, stating that Avecho Biotechnology Limited will present at the NWR Virtual Healthcare Conference on 21 March 2024. It invites shareholders and investors to register for the presentation and mentions that a recording will be available after the live session. The document does not contain any financial data, detailed financial reports, or regulatory filings. It is essentially an announcement about an upcoming investor presentation event, not the presentation itself or a financial report. Given the content and purpose, the document fits best as an Investor Presentation announcement (IP). However, since it is only announcing the presentation and not providing the presentation materials, it is more accurately classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other categories better. The document length is short (2378 characters), and it is not a report publication announcement. Therefore, the best classification is Regulatory Filings (RNS) with high confidence.
2024-03-17 English
Avecho meets TGA ahead of Phase III Clinical Trial 2 pages 71.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 14 March 2024 regarding a meeting with the Australian Therapeutic Goods Administration (TGA) about the Phase III clinical trial design for Avecho Biotechnology Limited's insomnia treatment. It discusses regulatory interactions, trial design confirmation, and plans to commence patient recruitment. There are no financial statements, earnings data, or detailed financial analysis present. The document is a corporate announcement about regulatory and clinical trial progress rather than a financial report or detailed investor presentation. It is not a report publication announcement since it does not mention the release or availability of a report, nor is it a certification or legal proceeding. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial progress and regulatory feedback, which does not fit into other more specific categories.
2024-03-13 English
AVE receives final ethics approval for Phase III CBD trial 2 pages 79.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 7 March 2024 regarding Avecho Biotechnology Limited receiving Ethics Approval for amendments to its Phase III clinical trial for insomnia. The content focuses on clinical trial progress, ethics approval, patient recruitment plans, and company statements. There are no financial statements, regulatory certifications, voting results, or management changes. The document is an announcement of a clinical trial milestone and operational update rather than a financial report or regulatory filing. It is not a full report like an Annual Report or Interim Report, nor is it a call transcript or investor presentation. The document is a regulatory announcement informing the market about a significant development in the company's clinical trial program. Given the nature and length (6364 characters), it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-03-06 English
Appendix 4E and Annual Report 31 December 2023 58 pages 2.8MB
Annual Report Classification · 100% confidence The document is titled 'Avecho Biotechnology Limited Appendix 4E Preliminary final report' and covers the financial year ended 31 December 2023. It includes detailed financial results, directors' report, auditor's report, consolidated financial statements, and notes. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. It contains comprehensive financial data, operational review, capital raising details, and audit information. The presence of an auditor's report and full financial statements confirms this is the official annual report. The document also states that the annual report for the year ended 31 December 2023 is attached, and then proceeds to include it. Therefore, this document is the full Annual Report (10-K equivalent) for the company for the fiscal year 2023. FY 2023
2024-02-28 English
Appendix 4G and Corporate Governance Statement 25 pages 727.3KB
Governance Information Classification · 100% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a detailed disclosure related to corporate governance practices and compliance with ASX Corporate Governance Council recommendations for the financial year ended 31 December 2023. The document includes a key to where governance disclosures can be found, and it explicitly states it is not a substitute for the corporate governance statement but a verification tool. It does not contain financial statements or management discussion of financial results but focuses on governance disclosures and compliance. This type of document aligns with Governance Information filings, which detail internal rules, board structure, and governance practices. The document length (15,000 characters) and content confirm it is a substantive governance disclosure, not merely an announcement or certification. Therefore, the appropriate classification is Governance Information (CGR).
2024-02-28 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.